Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Non-cash Items (2017 - 2024)

Rhythm Pharmaceuticals (RYTM) has disclosed Non-cash Items for 7 consecutive years, with $4.6 million as the latest value for Q4 2024.

  • On a quarterly basis, Non-cash Items rose 16.33% to $4.6 million in Q4 2024 year-over-year; TTM through Dec 2024 was $4.6 million, a 16.33% increase, with the full-year FY2024 number at $4.6 million, up 16.33% from a year prior.
  • Non-cash Items was $4.6 million for Q4 2024 at Rhythm Pharmaceuticals, up from $3.9 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $74.0 million in Q4 2022 to a low of $3.2 million in Q4 2021.
  • A 4-year average of $21.4 million and a median of $4.3 million in 2023 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: skyrocketed 2202.24% in 2022, then crashed 94.68% in 2023.
  • Rhythm Pharmaceuticals' Non-cash Items stood at $3.2 million in 2021, then surged by 2202.24% to $74.0 million in 2022, then plummeted by 94.68% to $3.9 million in 2023, then increased by 16.33% to $4.6 million in 2024.
  • Per Business Quant, the three most recent readings for RYTM's Non-cash Items are $4.6 million (Q4 2024), $3.9 million (Q4 2023), and $74.0 million (Q4 2022).